{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-003010","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.270757+00:00","generated_at":"2026-06-15T13:50:24.224578+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"CNS Pharmaceuticals appoints Bettina Cockroft, M.D., M.B.A. to Board of Directors","bullets":["Appointed Bettina Cockroft as independent director effective May 3, 2023; no committee assignments at this time.","Granted ten-year option for 8,300 shares at $1.67, vesting monthly over 36 months.","Cockroft is SVP/CMO of Sangamo Therapeutics, with over 30 years biopharma experience.","Standard non-employee director compensation applies, as described in prior SEC filings."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-003010","json":"https://secwatch.observer/filing/0001683168-23-003010.json","markdown":"https://secwatch.observer/filing/0001683168-23-003010.md","text":"https://secwatch.observer/filing/0001683168-23-003010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823003010/0001683168-23-003010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823003010/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:50:24.224578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67310e789f","claim":"Bettina M. Cockroft was appointed as Independent Director at CNS Pharmaceuticals, Inc..","evidence_excerpt":"On May 3, 2023, the Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) appointed Bettina M. Cockroft, M.D., M.B.A as an independent member of the Company’s Board of Directors effective on such date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823003010/0001683168-23-003010-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}